June 26, 2024

PPMD Convenes Leading Experts to Discuss Topics in Becker Care Ahead of 30th Annual Conference

Leading into PPMD’s 30th Annual Conference, PPMD is excited to host a professional meeting focusing on Becker muscular dystrophy care. Over the course of two days, attendees from across subspecialties, academic medical centers, and industry…

Learn More

October 18, 2022

Edgewise Announces 6 Sites Enrolling for CANYON, Phase 2 Trial of EDG-5506 in Becker

Edgewise has shared a community letter announcing that six sites are now open for enrollment for the Canyon trial for individuals living with Becker muscular dystrophy. Canyon is a Phase 2 trial of EDG-5506, a…

Learn More

September 16, 2022

ImagingNMD: Expanding Natural History Studies in Duchenne, Becker, and Carriers

Are you interested in contributing to clinical research to understand how muscle changes over time in Duchenne, Becker, and manifesting carriers? University of Florida’s ImagingNMD group has several studies currently recruiting participants to better understand…

Learn More

September 12, 2022

Edgewise Announces 4-Month Interim Results from ARCH Open Label Study of EDG-5506 in Adults with Becker

Edgewise Therapeutics has released 4-month interim results from the ongoing ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy. EDG-5506 is a small molecule, taken orally, that is intended to help protect muscle…

Learn More

September 7, 2022

Edgewise Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 in Participants with Duchenne

Edgewise Therapeutics has announced the FDA has authorized the initiation of the LYNX Phase 2 clinical trial of EDG-5506 in participants with Duchenne. EDG-5506 is a small molecule, taken orally, that is intended to help protect muscle by reducing…

Learn More

July 15, 2022

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial Of EDG-5506 In Individuals With Becker Muscular Dystrophy

PPMD is excited to share that Edgewise Therapeutics has announced CANYON, their Phase 2 study of EDG-5506 in individuals with Becker, is now enrolling. EDG-5506 is a small molecule, taken orally, that is intended to…

Learn More

June 20, 2022

Edgewise Announces Positive 2-Month Interim Results from Open Label Study of EDG-5506 in Adults with Becker

Edgewise Therapeutics has announced 2-month interim results from the ongoing ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy. Results showed that EDG-5506 significantly lowered muscle damage biomarkers in adults with Becker,…

Learn More

April 15, 2022

Edgewise-Funded Natural History Trial Of Becker Muscular Dystrophy Now Enrolling

Edgewise Therapeutics has announced the start of an observational trial in participants with Becker muscular dystrophy to understand the disease progression as assessed by functional measures and imaging endpoints. The trial is expected to recruit…

Learn More

January 5, 2022

Edgewise Therapeutics Announces Positive Topline Results From EDG-5506 Phase 1b Trial in Adults With Becker

Edgewise Therapeutics today announced positive topline results from the Phase 1b clinical trial of EDG-5506 in Becker muscular dystrophy. EDG-5506 is an oral small molecule muscle stabilizer which seeks to protect the muscle from injuries…

Learn More

December 15, 2021

Edgewise Initiates ARCH Follow-On Open Label Becker Study; Will Report Phase 1b Topline Results on January 5

Edgewise Therapeutics has announced the initiation of the ARCH open label study of EDG-5506 in Becker muscular dystrophy, which will enroll participants from its Phase 1b clinical trial as well as new participants with Becker….

Learn More